Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications

Irene Paraboschi a, Stephen Turnock b, Gabriela Kramer-Marek b, Layla Musleh c, Marta Barisa d, John Anderson d,e, Stefano Giuliani a,d,e,*

a Welcone/ERSRC Centre for Interventional & Surgical Sciences, University College London, London, UK
b Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
c Department of Specialist Neonatal and Pediatric Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
d Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK
e Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, England, UK

1. Introduction

For over half a century, cancer treatment has relied on the well-established triad of surgery, chemotherapy and radiotherapy. In particular, long-term oncological outcomes have been closely associated with the success or failure of complete surgical resection of the primary tumour (Nagaya et al., 2017a). Several studies have shown a clear correlation between subtotal microscopic resections and higher local recurrences in head and neck (Haque et al., 2019), urological (Wieder and Soloway, 1998; Dotan et al., 2007) and intestinal cancers (Nagtegaal and Quirke, 2008), culminating in poor patient outcomes. However, performing a complete tumour excision often presents a major challenge for surgeons. This is mainly due to the difficulty in clearing microscopic residual disease at the margins of resection, in particular when the tumours infiltrate or encase vital organs and vasculature. This limitation is common among all the surgical specialties and there is a need for novel adjuvant treatments capable of consolidating loco-regional control to reduce the risk of disease progression and metastatic spread.

External beam radiotherapy (EBR), chemotherapy and immunotherapy are common adjuvant treatments to eradicate residual cancer cells after surgery, but have significant limitations. Briefly, the disadvantages of EBR include damage to healthy surrounding tissues, failure to treat tumour areas that are not included in the radiation field, and increased incidence of secondary malignancy (De Ruyscher et al., 2019). Chemo- and immunotherapy are systemic consolidation approaches towards residual cancer cells, but the therapy can also be associated with significant side effects (e.g. cytokine release syndrome, inflammatory response, skin rash, colitis) and lead to autoimmune disorders (Su et al., 2020; Amos et al., 2011).

Photodynamic therapy (PDT) is a non-selective treatment method based on the combination of a photosensititive compound (photosensitiser, PS), visible light and tissue oxygen, none of which is toxic to cells or tissues by itself. The activation of a light-absorbing compound initiates processes leading to the destruction of the target cells (van Straten et al., 2017; Kwiatkowski et al., 2018). Nonetheless, delivery of the photosensitiser in PDT lacks tumour specificity and off-target and...
cutaneous toxicities may be observed.

Near-InfraRed PhotolImmunoTherapy (NIR-PIT) is emerging as a promising technique aiming to selectively kill cancer cells while leaving the host tissues and organs undamaged (Kobayashi and Choyke, 2019). The conjugation of the PS to an antigen specific monoclonal antibody (moAb) enables selective targeting the tumour, reducing potential side effects from NIR-PIT compared to PDT (Kobayashi et al., 2020a).

Here we present current evidence on NIR-PIT mechanisms of action and discuss the most recent preclinical and clinical studies demonstrating the utility of this novel adjuvant treatment.

2. Near-infrared photoimmunotherapy: mechanisms of action

In NIR-PIT the PS is conjugated to a highly specific monoclonal antibody (moAb) that has the ability to engage the selected target of interest, permitting an enhanced tumour specificity over PDT. Recent developments in antibody engineering technology have led to a new wave of PIT-suitable agents that are built on a range of moAbs, fragments and affibodies (Watanabe et al., 2015; Wei et al., 2020; Yamaguchi et al., 2019). Various PSs have been tested for NIR-PIT purposes and the silicon phthalocyanine dye, IRDye700DX has, so far, shown the most favourable properties (Kobayashi and Choyke, 2019). IRDye700DX has three diamagnetic silicones, which make it an efficient producer of singlet oxygen, and a high photostability compared to other commonly used dyes (Sato et al., 2018).

The highly selective cancer cell death induced by the NIR-PIT could be explained by the following non mutually exclusive mechanisms of action:

2.1. Oxidative stress

Conventional PDT has primarily worked through the production of singlet oxygen species (SOS) and reactive oxygen species (ROS) following NIR irradiation which are responsible for the necrotic cell death (van Straten et al., 2017; Kwiatkowski et al., 2018). However, the mechanisms by which SOS and ROS contribute to NIR-PIT induced cell death remain a matter of debate among experts in the field. In 2017, Raikar et al. (Raikar et al., 2017) showed that NIR-PIT produced significant levels of SOS and ROS in both in vitro and in vivo experiments performed by using UMUC-5 cells, a bladder squamous cell carcinoma (SCC) line. Moreover, they were able to completely rescue the NIR-PIT induced cell death with the addition of antioxidant agents such as NaN₃ (SOS quencher) and Trolox (ROS quencher).

On the other hand, the treatment with SOS (NaN₃) and ROS (i.e. N-acetyl cysteine, glutathione, 4-hydroxy TEMPO) scavengers only partially inhibited the phototoxicity effects of NIR-PIT in the experimental studies run by Mitsunaga et al. (Mitsunaga et al., 2011) and by Jin et al. (Jin et al., 2016) using 3T3/HER2 and MDA-MB-231 cells, respectively.

More recently, mass spectrometry (MS) was employed to investigate whether the oxidation of lipid molecules by ROS could be responsible for NIR-induced membrane disruption (Kobayashi and Choyke, 2019). Here, the analysis showed that the major component in the lipid membrane, the 16 – 1 phosphatidylcholine, was only minimally oxidised therefore suggesting possibly a minor role played by ROS in the physical stress of the cellular membrane. However, Kono et al. (Kono et al., 2020) demonstrated IR700 modified liposomes were disrupted through oxidation of cholesterol in the lipid membranes following NIR-irradiation. This was then inhibited through SOS (NaN₃) scavenging. The authors also showed that liposome disruption was enhanced in deoxygenated conditions, suggesting alternative mechanisms are taking place instead of oxidative stress. Further studies are needed to elucidate the effect of SOS/ROS on the cell membrane disruption and the subsequent cell death.

2.2. Axial ligand-release

Sato et al. (Sato et al., 2018) have detailed physical changes produced by the moAb-IR700 conjugate when bound to the cancer cell surface. These modifications, initiated by NIR-light, may cause physical stress and disruption of the cell membrane. MS analyses have shown that an axial ligand (C₁₂H₂₃NO₃S₄Si) is released from the IR700 after irradiation at 690 nm. Using frequency modulation-atonic force microscopy (FM-AFM) and gel-electrophoresis analyses, the authors demonstrated changes in the hydrophilicity of the conjugate with consequent alteration of its shape and solubility. This led to a propensity of the moAb-IR700 conjugate to aggregate, leading to the disruption of the transmembrane osmotic gradient (Fig. 1). As a result, cells began swelling, blebbing and bursting (Fig. 2), as demonstrated by 3D dynamic low coherence quantitative phase microscopy (3D LC-QPM) and dual-view inverted selective plane illumination microscopy (diSPIM).

Recently, Kobayashi et al. (Kobayashi et al., 2020b) have provided a theoretical mechanism by which the IR700 axial-ligand is released. Through NIR irradiation, a radical anion form of IR700 is produced upon which water molecules cleave a central Si–O bond through an acid-base protonation reaction. This hydrolysis reaction releases the Si axial-ligand and results in cell damage. This mechanism is supported by previous work by Anderson et al. (Anderson et al., 2016, 2018) thereby the authors also demonstrated that activating a silicon phthalocyanine by 690 nm light in hypoxic conditions resulted in cell death in adjacent, non-irradiated target cells. Therefore, the axial ligand release may be the primary damaging mechanism in hypoxic tissue, whereby the production of ROS and SOS is compromised by the low tissue oxygen levels.

2.3. Host anti-cancer immune response

Irrespective of the mechanism responsible for the NIR-induced cell death, the consequent swelling and bursting represent an uncontrolled and rapid cell death. This phenomenon inherently alerts the immune system to danger in contrast with the controlled, non-immunogenic apoptotic pathway of cell death. Rapid cell lysis leads to the release of cytoplasmic antigens and damage-associated molecular patterns (DAMPs) in the extracellular space, which activates the host immune system against the dying tumour cells (Garg et al., 2010). Consequently, the direct cytotoxic effects of NIR-light irradiation are further enhanced by the activation of the host anti-cancer immune response (Kobayashi and Choyke, 2019; Ogawa et al., 2017; Nagaya et al., 2019). Dendritic cells (DCs) are fundamental cells in the adaptive and innate immune system. Garg et al. (Garg et al., 2012) have shown that DCs increase the expression of maturation and costimulatory markers (i.e. CD80, CD86, CD40 and HLA-DR) when in co-culture with NIR-PIT treated tumour cells. Then mature DCs prime and educate naïve T cells leading to proliferation and cell-mediated cancer cell killing. DCs upregulate the transcription of the IL-12 cytokine gene, which promotes the development of a Th₁ response and this is a potent inducer of IFNγ production by T cells and NK cells (Ogawa et al., 2017). As a consequence of DC maturation, a systemic polyclonal T-cell response was initiated by NIR-PIT during in vivo studies and resulted in complete tumour rejection at both primary and distant sites when combined with PD-1 checkpoint blockade (Nagaya et al., 2019) (Fig. 3).

3. NIR-PIT: preclinical studies

Several preclinical feasibility mouse studies have investigated potential breakthroughs of NIR-PIT for the treatment of solid tumours. The most significant are grouped and illustrated based on the body system involved, as reported in Table 1. The majority of studies have been performed using human tumour systems in immunodeficient mice where there can be no contribution of host adaptive immune system to tumour control. We therefore categorise studies as those performed syngeneic immune competent hosts or immunodeficient xenograft...
studies and identify the mouse backgrounds per study. In mice such as NSG lacking T, B and NK cells, tumour control efficacy can be attributable to direct killing of tumour cells but without the involvement of the immune system.

3.1. Urological tumours

Bladder cancer (BC) is the sixth most common tumour worldwide. Although the majority of patients present with early-stage disease, BC recurrence is one the highest among all solid tumours, likely due to the persistence of minimal residual disease after primary surgery (Burger et al., 2013; Sylvester et al., 2006). The epidermal growth factor receptor (EGFR) is overexpressed in up to 74% of BC tissue specimens (Chaux et al., 2012). EGFR has relatively low expression in the normal urothelium (Rotterud et al., 2005), and its predominant luminal location in urothelial tumours (Messing, 1990) has therefore made the antigen a very promising therapeutic target for locally-advanced BCs. Railkar et al. (Railkar et al., 2017) first investigated the role of NIR-PIT as a new selective therapeutic strategy for EGFR-positive BCs in 2017. Mouse xenograft models of a subcutaneous EGFR-overexpressing BC xenograft (UMUC-5) showed a significant attenuation of tumour growth when treated with 120 μg of anti-EGFR-IR700 and irradiated at 24 h (100 J/cm²) and 48 h (50 J/cm²) post-administration; with a third of tumours completely regressing. Further, the authors showed no effect on tumour growth in immunodeficient mice bearing EGFR-low expressing BC xenografts (UMUC-3) with the same treatment regimen.

The role of anti-CD47 NIR-PIT in human BC cell lines (UMUC-3; HT-1376; 639 V) were also reported by Kiss et al. (Kiss et al., 2019), where the authors further demonstrated NIR-PIT induced cell death in BC primary cell lines derived from fresh surgical samples from 5 patients undergoing bladder cancer surgery. CD47 is a surface protein widely expressed on BCs, but absent in terminally differentiated luminal umbrella cells (Chan et al., 2009). Using subcutaneous xenograft models in NSG mice of CD47-overexpressing BCs, Kiss et al. (Kiss et al., 2019) showed that a single treatment with 200 μg of anti-CD47-IR700 followed by 100 J/cm² (on day 1) and 50 J/cm² (on day 2) of NIR-light resulted in a reduction of tumour growth compared with control mice receiving no treatment, anti-CD47-IR700 only or NIR-light only. Implementing this regimen over a 5-week treatment period, by repeating the injection of 200 μg of anti-CD47-IR700 followed by 100 J/cm² (on day 1), NIR-PIT treatment further slowed down tumour growth and improved mouse survival in comparison to untreated controls or mice receiving only the anti-CD47-IR700 conjugate. Since antibodies targeting CD47 are an emerging field of immune-oncology through the promotion of tumour phagocytosis, it will be of interest to determine the extent to which macrophages are involved in tumour clearance following PIT (Smolle and Pichler, 2017).

Prostate cancer (PC) is the most common malignancy in men and the third cause of cancer-related death in the United States (Siegel et al., 2017). Amongst all PC specific markers, anti–prostate-specific membrane antigen (PMSA) is one of the most studied targets due to its abundant expression in nearly all PCs, especially in the most poorly differentiated, more aggressive and hormone-refractory subtypes (Nagaya et al., 2017b). Anti-PSMA-IR700 PIT has been reported pre-clinically and shown to inhibit tumour growth in athymic nude mice bearing xenograft PSMA-positive PC tumours. After receiving three cycles of 100 μg of anti-PSMA-IR700 followed by the exposure to 50 J/cm² (on day 1) and 100 J/cm² (on day 2) of NIR-light, there was also an associated prolonged survival compared to the control mice (Nagaya et al., 2017b). The promising results achieved by this study advocate more investigations to confirm the role of anti-PSMA NIR-PIT as a new treatment modality for PCs, especially for early-stage diseases and loco-regional pelvis recurrences.
Fig. 2. *In vitro* morphological changes following affibody-based PIT. Incubation of U87-MGvIII spheroids with the ZEGFR:03115-IR700DX for 6 h and irradiation with a red LED (16 J/cm²) induced phototoxic cell death and disintegration of the architectural structure of the spheroid population (Courtesy of Dr Gabriela Kramer-Marek) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
3.2. Gastro-intestinal tumours

Due to their late presentation and their indolent course, gastro-intestinal malignancies are usually lethal and associated with a high rate of local recurrence and distant spreading (Maawy et al., 2015).

One of the most aggressive gastro-intestinal tumours is pancreatic cancer. In this regard, a significant decrease in tumour size was reported in athymic nude mice bearing carcinoembryonic antigen (CEA)-positive orthotopic pancreatic cancers treated with 100 μg of anti-CEA-IR700 and exposed to 270 J/cm² NIR light (690 nm) 24 h later (Maawy et al., 2015).

The common multifocal nature of hepatocellular carcinoma (HCC) makes it one of the best candidates for targeted drugs and high expression of glypican-3 (GPC3) in HCC makes NIR-PIT a very appealing treatment strategy for this tumour. Hanaoka et al. (Hanaoka et al., 2015) compared the efficacy of a whole anti-GPC3 IgG antibody (YP7) to a genetically engineered small heavy-chain anti-GPC3 antibody (NH3) for NIR-PIT in athymic nude mouse models of HCC. Under the same experimental conditions, comparable cell death was seen for both antibodies in vitro over a wide range of energies and in vivo using a regime of 50, 100 and 100 J/cm² NIR-PIT on three consecutive days. Interestingly, the smaller NH3-IR700 conjugate showed a more favourable pharmacokinetic profile with a more homogeneous distribution within the tumour, indicating higher penetration of NH3. Further, the authors showed a lower re-accumulation of NH3-IR700 compared to YP7-IR700 24 h after the first NIR-light exposure. All these findings indicated that NH3 could be a promising platform for designing molecularly targeted agents against HCC.

NIR-PIT has also shown some promising results for the treatment of the peritoneal carcinomatosis usually associated with advanced gastric cancers (Sato et al., 2014). Using GFP-transduced N87-GFP cells, Sato et al. (Sato et al., 2014) highlighted the efficacy of 100 μg of anti-HER2-IR700 conjugate (trastuzumab-IR700) in treating HER2 antigen-positive disseminated peritoneal gastric cancers in athymic nude mice. The authors showed a significant reduction in the tumour GFP fluorescence intensity when exposed to 50 J/cm² on day 1 and 100 J/cm² (on day 2) after the initial drug injection.

Glycoprotein A33 antigen (GPA33) is highly expressed in over 95% of human colorectal cancers, the second leading cause of cancer-related death worldwide (Bray et al., 2018). The efficacy of NIR-PIT in combination with a single-chain antibody variable fragments for GPA33 (A33scFv) has been investigated in a recent study published by Wei et al. (2020). The A33scFv displayed specific binding to GPA33-positive colorectal tumour cells (LS174 T) in vitro and a single round of NIR-PIT (100 μg of A33scFv-IR700 iv + 120 J/cm² NIR-light 4 h post-injection) markedly suppressed tumour growth without apparent systematic off-targeted effects in vivo experiments employing BALB/C nu/nu mice. Their results suggested that scFv-IR700 conjugates may represent an attractive approach for tumour treatment, increasing tumour penetration and allowing rapid systemic clearance, in this way reducing the risks of side-effects.

3.3. Lung tumours

Pulmonary cancer is the most common cause of tumour-related death worldwide while the lung is the most common site of spreading of distant metastases (Sato et al., 2015a). About 80% of lung cancers are histologically classified as non-small cell lung carcinoma (NSCLC), which patient prognosis is further worsened by the frequent occurrence of pleural metastasis in more advanced disease (Sato et al., 2015a).

NIR-PIT effects in models of pleural disseminated HER2-positive NSCLCs (Ca-lu3-luc-GFP cells) were investigated by Sato et al. (Sato et al., 2015a). By using the Olympus BP-XP-60 fluorescent thoracoscopy, a significant decrease in the GFP-fluorescence and IR700-fluorescence intensity was observed as the result of the transcutaneous application of NIR-light (50 J/cm² on day 1 and 100 J/cm² on day 2) in athymic nude mice receiving of 100 μg of anti-HER2-IR700 (trastuzumab-IR700). Notably, despite a small pleural effusion present in one out of seven mice, histological analyses excluded any apparent damage to the surrounding normal lung.

Moreover, Sato et al. (Sato et al., 2015b) have also reported that a single dose of anti-HER2 NIR-PIT (100 J/cm² of NIR-light 24 h after the injection of 100 μg of trastuzumab-IR700) using a HER2-positive (3T3/HER2-luc-GFP) mouse model of lung metastases was sufficient to cause a significant reduction in the volume of tumour metastasis in vivo. However, multiple NIR-PIT exposures (100 μg of trastuzumab-IR700 on day 13, 15, 17 and 19 followed by 100 J/cm² NIR-light 24 h post each APC injection) were required to improve the overall mouse survival.

A similar athymic nude mouse model of lung metastasis (consisting of 3T3-RFP, 3T3/HER2-luc-GFP and mixtures of 3T3-RFP and 3T3/HER2-luc-GFP) was also adopted to confirm the selective action of NIR-PIT on HER2-positive tumour cells (Sato et al., 2015c). No damage to the adjacent normal lung tissue or to non-targeted tumour cells was reported after the thoracic exposure to NIR-light at 50 J/cm² 24 h after the tail vein injection of 100 μg of anti-HER2-IR700 conjugate.

Promising results were also achieved by Nakamura et al. (Nakamura et al., 2017) who investigated the therapeutic effects of NIR-PIT in a transgenic mouse model of spontaneously occurring EGFR-positive lung adenocarcinomas arising in mice with intact immune systems. Three cycles of 150 μg of anti-EGFR-IR700 (panitumumab-IR700) followed by the irradiation with NIR-light from two directions (each 20 J/cm², via the back and the front) significantly reduced tumour growth as measured by serial Magnetic Resonance Imaging (MRI).

Furthermore, conjugates targeting programmed cell death-ligand 1...
Table 1
The main preclinical feasibility studies investigating the potential breakthroughs of NIR-PIT for the treatment of solid tumors.

| Cancer type                                      | Antigen targeted | Conjugated Cell lines used in in vivo experiments | Mice models                  | Amount of conjugated injected | NIR light dose and timing |
|-------------------------------------------------|------------------|--------------------------------------------------|------------------------------|-------------------------------|---------------------------|
| **Urological tumors**                            |                  |                                                  |                              |                               |                           |
| (Railkar et al., 2017)                            | Bladder cancer   | EGFR Anti-EGFR moAb (Panitumumab)               | UMUC-5; UMUC-3               | 120 ug once (sc model)         | 100 J/cm² (day 1) + 50 J/cm² (day 2) |
| (Kim et al., 2019)                               | Bladder cancer   | CD47 B6H12                                      | Immuno-compromised NSG       | 200 ug once (sc model)         | 100 J/cm² (day 1) + 50 J/cm² (day 2); 100 J/cm² (day 1) + 50 J/cm² (day 2) (at week 1), 100 J/cm² (day 1) only (for week 2-5) |
| (Nagaya et al., 2017a)                           | Prostate cancer  | PMSA Anti-PMSA moAb                             | PC3                          | 100 μg weekly for 3 weeks (sc model) | 50 J/cm² (day 1) + 100 J/cm² (day 2) (for 3 weeks) |
| **Gastrointestinal tumors**                      |                  |                                                  |                              |                               |                           |
| (Maowy et al., 2015)                             | Pancreatic cancer | CEA Anti-CEA moAb                                    | BxPC-3                      | 100 μg (orthotopic model)      | 270 J/cm² (day 1)         |
| (Ishuoka et al., 2015)                           | Liver cancer     | GPC3 YP7;HN3                                     | A431/G1                     | 68.5 μg (HN3) (sc model)       | 50 J/cm² (day 1) + 100 J/cm² (day 2) + 100 J/cm² (day 3) |
| (Sato et al., 2014)                              | Gastric peritoneal carcinomatosis | HER2 Anti-HER2 moAb (Trastuzumab) | N87                          | 100 μg (YP7) (sc model)        | 50 J/cm² (day 1) + 100 J/cm² (day 2) + 100 J/cm² (day 3) |
| (Wei et al., 2020)                               | Colorectal Tumors | GPA33 A233cV antibody                             | LS174 T, COLO205 BALB/C nu/nu mice | 100 μg (orthotopic model)      | 50 J/cm² (day 1) + 100 J/cm² (day 2) |
| **Lung tumors**                                  |                  |                                                  |                              |                               |                           |
| (Sato et al., 2015a)                             | Non-Small Cell Lung Carcinoma | HER2 Anti-HER2 moAb (Trastuzumab) | Calu3                       | 100 μg (sc model)              | 50 J/cm² (day 1) + 100 J/cm² (day 2) |
| (Nagaya et al., 2017c)                           | Papillary adenocarcinoma of the lung | PD-L1 Anti-PD-L1 moAb (Avelumab) | H441                        | 100 μg (sc model)              | 50 J/cm² (day 1) + 100 J/cm² (day 2) |
| (Nakamura et al., 2017)                          | Lung cancer expressing human EGFR | EGFR Anti-EGFR moAb (Panitumumab) | Transgenic mouse model of spontaneous lung cancer expressing human EGFR | 150 μg (orthotopic model) | 40 J/cm² (day 1) |
| (Sato et al., 2015b)                             | Lung metastasis  | HER2 Anti-HER2 moAb (Trastuzumab) | 3T3/HER2                     | 100 μg (sc model)              | 100 J/cm² (day 1)         |
| (Sato et al., 2015c)                             | Lung metastasis  | HER2 Anti-HER2 moAb (Trastuzumab) | 3T3/HER2                     | 100 μg (orthotopic model)      | 100 J/cm² (day 1)         |
| **Head and neck tumors**                         |                  |                                                  |                              |                               |                           |
| (Nagaya et al., 2017d)                           | Oral Cavity Squamous Cell Carcinoma (OSCC) | CD44 Anti-CD44 | MOC1, MOC2-luc, MOC2-mKate2 | 100 μg (unilateral sc model) | 50 J/cm² (day 0) + 100 J/cm² (day 1) |
| (Sato et al., 2015d)                             | Disseminated peritoneal ovarian cancer | HER2 Anti-HER2 moAb (Trastuzumab) | SKOV                        | 100 μg (bilateral sc model)  | 100 J/cm² (day 0) + 100 J/cm² (day 1) |
| (Nagaya et al., 2015)                            | Triple-negative breast cancer | EGFR Anti-EGFR moAb (Cetuximab) | MDAMB231, MDAMB468          | 100 μg (sc model)              | 50 J/cm² (day 1) + 100 J/cm² (day 2) |

(continued on next page)
Anti-PD-L1-IR700 showed high tumour accumulation and high antigens in athymic nude mice (Nagaya et al., 2017c). Oous models of lung papillary adenocarcinomas overexpressing PD-L1 (PD-L1-IR700) induced significant therapeutic responses in subcutane

Abbreviations. Sc: subcutaneous.

| Cancer type                  | Antigen targeted | Conjugated      | Cell lines used in in vivo experiments | Mice models                        | Amount of conjugated injected | NIR light dose and timing |
|------------------------------|------------------|-----------------|---------------------------------------|------------------------------------|------------------------------|---------------------------|
| (Jin et al., 2016)           | Triple-negative breast cancer | CD44 | Anti-CD44 moAb | MDA-MB-231, BT-474 | Athymic Balb/c (nu/nu) mice | 100 μg (sc model, one shot regimen) | 30 J/cm² (day 1) |
|                              |                  |                 |                                       |                                    | 300 μg (sc model, one shot regimen) | 30 J/cm² (day 1) |
|                              |                  |                 |                                       |                                    | 100 μg every week for 2 weeks (sc model, two shot regimen) | 30 J/cm² (day 1) |
| (Yamaguchi et al., 2019)     | Breast cancer    | HER2            | HER2 Affibody                         | SK-BR3, BT474, MDA-MB361           | na                          | na                        |
| Brain tumors                 |                  |                 |                                       |                                    | na                          | na                        |
| (Jing et al., 2016)          | Glioblastoma     | AC133/CD133     | Anti-AC133 moAb                      | CD133-EO U251, NCH421k            | Immunocompromised nude mice | 100 μg (sc model)         | 100 J/cm² (day 1) |
|                              |                  |                 |                                       |                                    | 100 μg (orthotopic model)       | 50 J/cm² (day 1) + 100 J/cm² (day 3) |
| (Barley et al., 2018)        | Glioblastoma     | EGFR            | Anti-EGFR affibody                   | U87-MGvIII                       | NCr athymic mice              | 18 μg (sc model)          | 100 J/cm² (hour 1) |

In this regard, Sato et al. (2015d) examined the cytotoxic effects of NIR-PIT in 3D spheroids composed of HER2-positive ovarian cancer cells. Repeated exposure to 2 J/cm² of NIR-light ultimately killed tumour cells previously incubated with anti-HER2-IR700 (trastuzuma-b-IR700). These results were also confirmed by in vivo studies, whereby a dramatic decrease in tumour volume and luciferase activity of human ovarian SKOV3-luc-D3 cells engrafted in athymic nude mice was achieved by exposing flank or disseminated peritoneal ovarian cancers to 100 J/cm² of NIR-light 24 h after the administration of 100 μg of the APC.

3.4. Head and neck tumours

Oral cavity squamous cell carcinoma (OSCC) is the sixth leading cause of cancer-related mortality worldwide. Its poor prognosis is most likely due to the advanced stage of disease at diagnosis and the high rate of loco-regional recurrence and distant metastasis (Kademani, 2007). The majority of head and neck tumours express CD44, a cancer stem-like antigen, for which targeting moAbs are currently under investigation in phase 1 clinical trials (Rupp et al., 2007; Sauter et al., 2007; Tijink et al., 2006; Menke-van der Houven van Oordt et al., 2016).

The immunological effects of anti-CD44 moAbs have been the focus of NIR-PIT studies involving syngeneic immuno-competent models of murine oral cancer (MOC), whose genetic alterations mirror human OSCC (Nagaya et al., 2017c). A significant tumour growth reduction associated with mouse survival improvements were seen after the irradiation with 50 J/cm² and 100 J/cm² of NIR-light, 24 and 48 h following the injection of 100 μg of CD44-IR700 conjugate, respectively. More interestingly, owing to the use of immunocompetent syngeneic mouse models and the use of bilateral subcutaneous MOC tumours, the authors were able to show a significant reduction in the size of the non-NIR-treated contralateral tumour as evidence of the activation of the host immune response.

3.5. Gynaecological tumours

Ovarian carcinoma is the leading cause of gynaecological cancer-related deaths throughout the world (Nath et al., 2019). The advanced stage disease at diagnosis, the difficulty of the surgical excision due to the strict adhesion of cancer implants into the peritoneum and the relatively rapid onset of chemo-resistance have contributed to a minimal improvement of the 5-year overall survival (OS) observed in the last few decades (Nath et al., 2019). Therefore, there is a desperate need for novel targeted cancer therapies that can selectively kill tumour cells while causing minimal damage to the adjacent healthy tissue.

(PD-L1-IR700) induced significant therapeutic responses in subcutaneous models of lung papillary adenocarcinomas overexpressing PD-L1 antigens in athymic nude mice (Nagaya et al., 2017c). Anti-PD-L1-IR700 showed high tumour accumulation and high tumour-to-background ratio. Tumour growth was significantly inhibited while causing minimal damage to the adjacent healthy tissue.
Furthermore, cell viability decreased in a NIR-light-dose and HER2 affibody-IR700 conjugate-concentration dependent manner. The employment of affibody molecules may offer unique opportunities in the clinical translation of NIR-PIT thanks to their rapid clearance and good tissue penetration. Moreover, Maczynska et al. (2020) demonstrated that the administration of a IR700-based HER2-targeted affibody conjugate can drive immunogenic cancer cell death and influence the innate and adaptive anti-tumour immune response when irradiated with NIR-light. These findings suggest that affibody-based PIT is an attractive alternative to moAb-based options, particularly for patients whose tumours acquire resistance to conventional anti-HER2 therapies.

### 3.6. Brain tumours

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. It shows particularly aggressive behaviour and invasiveness most likely due to the presence of CSCs in its advance front. AC133, an epitope of CD133, is a CSC marker for many malignancies, including GBM (Chen et al., 2016; Singh et al., 2004).

Interestingly, preclinical studies investigating the role of anti-AC133 NIR-PIT showed not only a significant reduction in tumour growth but also a delayed CSC-driven tumour initiation when subcutaneous CD133-positive GMB xenografts were treated with NIR-light (Jing et al., 2016). In fact, when $5 \times 10^6$ cells pre-irradiated for 14 h with 40 µg/ml of AC133-IR700 were bilaterally injected into the flanks of nude mice and unilaterally exposed to 100 J/cm², tumour growth inhibition only occurred in the side exposed to NIR-light. Moreover, a dramatic decrease in tumour volume and a significant increase in survival were reported in mice bearing orthotopic CD133-positive GBM xenografts trans-cranially irradiated with 50 J/cm² (on day 1) and 100 J/cm² (on day 3) of NIR-light after the administration of 100 µg of AC133-IR700.

Further, EGFR amplification occurs in about 50% of de novo primary GBMs, representing the most common genetic aberration in these patients. Recently, Burley et al. (2018) demonstrated that the administration of an affibody-NIR-activated conjugate targeting EGFR (Z_{EGFR:03115}-IR700) selectively induces GBM cell death with no detected toxicity in normal tissues in orthotopic brain tumour models employing NCr athymic mice. The high binding affinity of this affibody molecule, its small size and excellent tumour penetration make the conjugate ideal targeting agents for GBM therapy. In particular, their ability to cross the blood-brain barrier can be beneficial to clearly image and efficiently treat not only the brain primary tumours but also secondary metastases.

### 4. NIR-PIT: clinical trials in humans

Based on the promising results of many preclinical studies, the first-in-human phase 1/2a clinical trial for NIR-PIT started in June 2015 in patients with intractable recurrent head and neck squamous cell carcinoma (HNSCC) involving seven cancer centers in the US (https://clinicaltrials.gov/ct2/show/NCT02422979). The first part of this trial focused on the establishment of a recommended dose of the experimental drug. A parenteral formulation of cetuximab-IR700 (RM-1929) was administrated at three different doses ($160 \text{mg/m}^2$, $320 \text{mg/m}^2$, $640 \text{mg/m}^2$) 24 h prior to NIR-light irradiation (50 J/cm² for superficial lesions or 100 J/cm² for interstitial lesions).

The definition of the Drug Maximum Tolerated Dose (MTD), the Maximum Feasible Dose (MFD), the adverse event profile for each drug dose and the photo-safety of the applied NIR-light were the primary outcomes of this study, while the drug pharmacokinetic profile, the tumour response/reduction/necrosis and the immunogenic response were the secondary outcomes.

The second part of this trial investigated the safety and the anticancer efficacy of up to four repeated treatments of RM-1929 administered at the MFD ($640 \text{mg/m}^2$), and activated with a fixed amount of NIR-light: (i) 75 J/cm² for superficial lesions or 150 J/cm² for interstitial lesions; (ii) 100 J/cm² for superficial lesions or 200 J/cm² for interstitial lesions; (iii) 50 J/cm² for superficial lesions or 100 J/cm² for interstitial lesions.

Preliminary results of this two-part study confirmed human safety and the efficacy of RM-1929 NIR-PIT. Both tumour response and patient survival (overall response rate of 44.8%, median PFS of 5.7 months and median OS of 9.5 months) improved over conventional therapies in this highly selected group of patients (Gillenwater, ASCO 2018).

After receiving the Fast Track designation from the US Food and Drug Administration (FDA), a phase 3 randomised, double-arm clinical trial evaluating the effects of a parenteral formulation of cetuximab-IR700 (ASP-1929) started in May 2019 in 275 patients affected by recurrent HNSCC who have failed at least two lines of therapy (https://clinicaltrials.gov/ct2/show/NCT03769506). The trial is currently under way in the US, Belgium, Greece, Spain, Japan and Taiwan.

ASP-1929 efficacy will be disclosed by comparing the progression-free survival (PFS) and the OS of patients treated with repeated ASP-1929 PIT interventions (experimental arm) with those treated according to the physician’s choice standard of care (SOC), consisting of docetaxel, cetuximab, methotrexate or paclitaxel (control arm).

Moreover, in order to further improve its performance, NIR-PIT can be combined with conventional cancer immunotherapies, such as immune-checkpoint inhibitors. In this regard, a Phase 1b/2 clinical trial investigating the role of ASP-1929 administered in combination with anti-PD-L1 therapies in PD-L1 and EGFR-positive recurrent or metastatic HNSCCs (cohort 1) or PD-L1 and EGFR-positive locally advanced or metastatic cutaneous SCCs (cohort 2) is due to start in September 2020 (https://clinicaltrials.gov/ct2/show/NCT04305795). Anti-PD-L1 immunotherapy (200 mg of pembrolizumab in the cohort 1 and 350 mg of cemiplimab in the cohort 2) will be administered in addition to ASP-1929 to assess the safety, tolerability and tumour response of this combined regimen.

Alongside these APC studies, non-antibody mediated NIR-PIT has been employed in clinical trials investigating melanoma treatment. AU-011 is a novel established formulation of nanoparticles derived from the Human PapillomaVirus (HPV-NPs) conjugated to IR700. It selectively binds to specifically modified Heparan Sulphate Proteoglycans (HSPGs) which are upregulated in ocular melanoma cells. An ascending single and repeat dose clinical trial investigating the safety, the immunogenicity and the efficacy of intravitreally injected AU-011 for the treatment of 57 patients with Small Primary Choroidal Melanoma started in February 2017 and is currently underway in the US (https://clinicaltrials.gov/ct2/show/study/NCT03052127). Preliminary safety and efficacy results in terms of treatment-related adverse events, local tumour control and visual acuity preservation seem to be very promising.

### 5. NIR-PIT: therapeutic benefits, limits and challenges and future perspectives

NIR-PIT offers several advantages over conventional cancer treatments.

Firstly, moAb NIR conjugates can be used as a specific tool to track tumour cells and response to treatment from diagnosis to follow-up. As well, the same conjugate can be used as intraoperative imaging to help the surgeon to achieve a safer and more radical resection (Kobayashi et al., 2020c). In fact, optical qualities of IRDye700DX fluorophore (such as the limited photobleaching, the water solubility and salt tolerance) make it an excellent optical probe for moAb conjugation. Due to the diagnostic and therapeutic properties of this dye, the moAb-based IRDye700DX conjugates can be considered as theranostic agents. In addition, fibro-optical diffusers could be inserted through endoscopes, trocars, needles and catheters in order to widely visualise and administer NIR-PIT to airways, gastro-intestinal or urinary tumours (Kobayashi and Choyke, 2019).

Secondly, APC targeted action provides a tumour-cell specificity with virtually no damage to normal adjacent structures given the
appropriate choice of moAb specificity. These findings have been confirmed with both in vitro and in vivo studies, whereby free APC did not exert any detrimental effects on unbounded cells following NIR-light exposure. In fact, cell death efficiency was not increased by failing to wash cells from unbound conjugates prior to irradiation (Mitsunaga et al., 2011). By sparing adjacent normal cells, e.g. tumour-infiltrating immune cells, the innate and adaptive antitumour response can be further activated producing both local and systemic immune-activation.

In this way, the tumour cell killing induced by the direct cytotoxicity effects of NIR-light irradiation is enhanced by the host anti-cancer immune response to DAMPs. The systemic antitumour immunity induced by NIR-PIT aids in the clearance of distant metastases and the prevention of tumour recurrences (Kobayashi and Choyke, 2019; Nagay et al., 2019; Kobayashi et al., 2020c).

In addition, NIR-PIT exploits a form of non-ionising radiation. For this reason, no limits to its total cumulative dose have been reported, and multiple cycles of NIR-PIT could be safely employed.

Interestingly, increased permeability of tumour vessels follows the rapid NIR-PIT-induced death of the perivascular cancer cells. This phenomenon, named super-enhanced permeability and retention (SUPR), could be employed to allow for more efficient delivery of chemotherapeutic agents into the tumour bed (Kobayashi and Choyke, 2019; Sano et al., 2013; Hanaoka et al., 2015). In fact, in vivo studies have demonstrated that NIR-PIT dramatically increased the therapeutic effects of liposome-containing daunorubicin (Sano et al., 2013) and nanosized albumin-bound-paclitaxel when compared to either therapy alone.

Finally, this new generation of APC drugs have a similar pharmaco-kinetic profile of the native naked moAbs, resulting in highly targeted tumour accumulation with minimal non-specific binding (Sato et al., 2015d). The unbound IR700 water-solubility following its dissociation from the targeted cells results in a rapid urinary excretion with no long-lasting photosensitising effects, as proved by the preliminary results of early clinical trials (Kobayashi and Choyke, 2019).

However, some limitations of NIR-PIT have yet to be settled. Firstly, NIR-light penetration up to 10 mm may limit the application of NIR-PIT in the case of large tumour masses, reducing therapeutic opportunities to the intraoperative clearance of minimal residual disease or lymph node metastases.

Secondly, a single tumour-specific antigen is not always overexpressed in spontaneously occurring cancers. However, this limitation could be overcome by the administration of a cocktail of APCs against different tumour antigens, resulting in a more homogeneous intra-tumoural micro-distribution (Nakajima et al., 2013). Finally, most studies have been carried out in immunodeficient mice, most commonly athymic nude mice, and the contribution of host immune cells to tumour clearance has, therefore, not been appropriately investigated in most studies. The role of systemic antitumour immunity induced by NIR-PIT for the clearance of distant metastases and the prevention of tumour recurrences requires substantial further examination.

6. Conclusion

NIR-PIT is a recently developed molecularly-targeted cancer treatment that exploits a photochemistry-based process to kill tumour cells while selectively enhancing the host immune response. Preclinical feasibility studies and early results emerging from clinical trials have demonstrated the therapeutic potential of NIR-PIT, indicating this novel technique as a drug carrier for hepatocellular carcinoma therapy. Mol. Pharm. 12 (6), 234–241. https://doi.org/10.1021/jp410971q.

The work was supported by the Medical Research Council UK Clinical Academic Research Partnership (PI Stefano Giuliani, grant number MR/T005491/1) and by the Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS, grant number 203145/S/16/2) at the University College London, United Kingdom.

Declarations of Competing Interest

Nothing to declare.

Acknowledgments

None.

References

Amos, S.M., Duong, C.P.M., Westwood, J.A., et al., 2011. Autoimmunity associated with immunotherapy of cancer. Blood 118 (3), 499–509. https://doi.org/10.1182/blood-2011-01-225266.

Anderson, E.D., Gorka, A.P., Scherermann, M.J., 2016. Near-infrared uncaging or photosensitizing dictated by oxygen tension. Nat. Commun. 7, 13378. https://doi.org/10.1038/ncomms13378.

Anderson, E.D., Sova, S., Ivanic, J., Kelly, L., Scherermann, M.J., 2018. Defining the conditional basis of silicon phthalocyanine near-IR ligand exchange. Phys. Chem. Chem. Phys. 20 (28), 19030–19036. https://doi.org/10.1039/c8cp03842h.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394–424. https://doi.org/10.3322/caac.21492.

Burger, M., Catto, J.W.F., Dalbagni, G., et al., 2013. Epidemiology and risk factors of urethral bladder cancer. Eur. Urol. 63 (2), 234–241. https://doi.org/10.1016/j.eururo.2012.07.033.

Burley, T.A., Mażynska, J., Shah, A., et al., 2018. Near-infrared photodynamic therapy targeting EGFR-Shedding new light on glioblastoma treatment. Int. J. Cancer 142 (11), 2363–2374. https://doi.org/10.1002/ijc.31246.

Chan, K.S., Espinosa, I., Chao, M., et al., 2009. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 106 (33), 14016–14021. https://doi.org/10.1073/pnas.0906549106.

Chaux, A., Cohen, J.S., Schultz, L., et al., 2012. High epidermal growth factor receptor immunochemo-histochemical expression in urethral carcinoma of the bladder is not associated with EGFR mutations in exom 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum. Pathol. 43 (10), 1590–1595. https://doi.org/10.1016/j.humpath.2011.11.016.

Chen, R., Nishimura, M.C., Bumbaca, S.M., et al., 2010. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17 (4), 362–375. https://doi.org/10.1016/j.ccr.2009.12.049.

De Ruyscher, D., Niedermann, G., Burnet, N.G., Siva, S., Lee, A.W.M., Hegi-Johnson, F., 2019. Radiotherapy toxicity. Nat Rev Dis Primer 5 (1), 13. https://doi.org/10.1038/s41572-019-0064-5.

Diehn, M., Cho, R.W., Lobo, N.A., et al., 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458 (7239), 780–783. https://doi.org/10.1038/nature07733.

Dotan, Z.A., Kavanagh, K., Yosepowitch, O., et al., 2007. Positive surgical margins in soft tissue following radical cystectomy for bladder Cancer and Cancer Specific survival. J. Urol. 178 (6), 2308–2313. https://doi.org/10.1016/j.juro.2007.08.023.

Gard, A.D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D.V., Agostinis, P., 2010. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta BBa - Rev Cancer 1805 (1), 53–71. https://doi.org/10.1016/j.bbcan.2009.08.003.

Gard, A.D., Krysko, D.V., Verfaillie, T., et al., 2012. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31 (5), 1062–1079. https://doi.org/10.1038/emboj.2011.497.

Hanaoka, H., Nagaya, T., Sato, K., et al., 2015. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol. Pharm. 12 (6), 2151–2157. https://doi.org/10.1021/acs.molpharmaceut.5b00152.
Wellcome/EPSRC Centre for Interventional & Surgical Sciences, University College London, London, UK and Honorary Research Fellow at the Institute of Cancer Research, London, UK. Her research interests are focused on preclinical studies of Fluorescence-Guided Surgery and Near-InfraRed Photoimmunotherapy in Neuroblastoma.

Stephen Turnock received their BSc from King’s College London, UK before joining the Radiotherapy and Imaging department at The Institute of Cancer Research, London, UK in 2016. He obtained his PhD in Molecular Imaging under the supervision of Dr Gabriela Kramer-Marek. Stephen is currently undertaking a Postdoctoral Research Fellowship in radiation oncology, where they are particularly interested in the toxicity of proton radiotherapy to normal tissue.

Gabriela Kramer-Marek received her PhD degree in 2005 in Medical Physics from Silesian University, Poland and the following year she joined the Radiation Oncology Branch, NCI/NIH, USA to work on the development and characterisation of molecular probes for in vivo detection and quantification of tumour-specific markers. Her research resulted in multiple awards, including the Award for the Outstanding Postdoctoral Fellow of NCI 2010, NCI/NIH, USA. In January 2012, she accepted her first faculty position (Research Assistant Professor, non-tenure track) in the Department of Medicine, Indiana University School of Medicine, USA. Currently, she works as the Associate Professor at the Institute of Cancer Research in London leading the group of Preclinical Molecular Imaging. The central goal of her research is to link imaging studies, biological insights and translational opportunities.

Layla Musleh received from the University of Rome, Italy, a degree in Medicine in 2014 and she completed her traineeship in Paediatric Surgery at the Bambino Gesù Children’s Hospital, Rome, Italy, in 2020. She is currently a Paediatric Surgeon at the University Hospital Agostino Gemelli, Rome. Her research interests are related to photoacoustic imaging for Neuroblastoma treatment.

Marta Barisa is a translational oncoimmunotherapy specialist at Great Ormond Street Hospital Institute of Child Health, specialised in solid tumour targeting with genetically engineered cellular products. Marta trained at St. George’s Hospital Medical School University of London, UK, Massachusetts Institute of Technology, USA and University College London, UK.

John Anderson was appointed as a Clinical Lecturer in paediatric oncology at UCL Institute of Child Health in 1998 after completing his PhD, which he had undertaken as a clinical research fellow at the Institute of Cancer Research (1995–1998). In 2001 he was awarded a Cancer Research UK (then the Cancer Research Campaign) Clinician Scientist Fellowship (2002–2007). Since 2007, he held a HEFCE Senior Clinical Fellowship. During his first 7 years at ICH he completed his clinical training in Paediatrics and Paediatric Oncology, whilst establishing his own laboratory-based research group. In 2005 he gained Certificate of Completion of Specialist Training in Paediatrics and Paediatric Oncology and was appointed as Honorary Consultant Oncologist at Great Ormond Street Hospital. His research is mainly focused on novel immunotherapy approaches for childhood cancers and therapeutic methods for immune modulation. Since 2015 he has held a personal chair in experimental paediatric oncology at University College London Great Ormond Street Institute of Child Health where his research is focused on development and delivery of experimental biotherapeutics for childhood cancer.

Stefano Giuliani is a Consultant Paediatric Surgeon at Great Ormond Street Hospital for Children and Honorary Associate Professor at the University College London. He graduated in Medicine in 2000 at the University of Udine, Italy and became a specialist paediatric surgeon in 2006. He obtained a PhD in Developmental Biology and Planning Science in 2010 at the University of Padova. He spent four years in the USA (2006–2010) working in basic science research and doing a clinical fellowship at the Children’s Hospital Los Angeles. He has been working as a Consultant Surgeon in London since 2011.